Innocan Pharma Corporation (TSE:INNO) has released an update.
Innocan Pharma Corporation has reported promising results from its pharmacokinetic study on rabbits, showing long-term release of CBD from a single injection of its LPT-CBD platform. This success mirrors earlier animal studies and paves the way for upcoming human trials. The company aims to utilize this technology to enhance patient treatment for various conditions through controlled and sustained drug delivery.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.
